Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193185 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19FFAR2L3MBTL1UTS2R | |
| SCHEMBL2518887 | 0.86 | SLC2A1 (0.48) | UTS2RPOLBLMNAALDH1A1CA1 | |
| SCHEMBL16693879 | 0.84 | HDAC3 (0.42) | LMNAHSD17B10ALDH1A1 | |
| SCHEMBL10016157 | 0.82 | SLC6A2 (0.43) | CYP2C9CYP2C19FFAR2UTS2RALDH1A1 | |
| SCHEMBL15948294 | 0.82 | SLC6A2 (0.43) | CYP2C9CYP2C19FFAR2UTS2RALDH1A1 | |
| SCHEMBL15958526 | 0.82 | UTS2R (0.39) | CYP2C9CYP2C19FFAR2UTS2RALDH1A1 | |
| SCHEMBL9071483 | 0.81 | UTS2R (0.39) | CYP2C9CYP2C19FFAR2UTS2RALDH1A1 | |
| SCHEMBL2194696 | 0.81 | ALOX15 (0.52) | CYP2C9CYP2C19FFAR2L3MBTL1POLB | |
| SCHEMBL1356006 | 0.81 | ALOX15 (0.52) | CYP2C9CYP2C19FFAR2L3MBTL1POLB | |
| SCHEMBL1393495 | 0.80 | KMT2A (0.56) | CYP2C9CYP2C19FFAR2L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8445538-B2 | Glucagon receptor antagonist compounds | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445538-B2 | Glucagon receptor antagonist compounds | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-10-13 | — | — | US | disclosed |
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-10-13 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010071750-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | GLP1R, GCGR, GPR119 | CYP2C9 2487/4885CYP2C19 2247/4885FFAR2 30/4885 |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | CYP2C9 2747/4885CYP2C19 2134/4885FFAR2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.